[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612022":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":33,"responsibleParty":49,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":31,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":31,"enrollmentInfo":64,"targetDuration":31,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":31,"overallStatus":36,"whyStopped":31,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Bioray Laboratories","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group","EXPERIMENTAL","5.0-10×10\\^6cells\u002Fkg",[13],"Drug: Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection","The study drug is administered intravenously at a fixed dose within 1-2 days after lymphocyte depletion, and its efficacy and safety are observed.",[9],[21],"BRL-305",[23],{"name":24,"affiliation":25,"role":26},"Ping Li, PhD","13564181131","STUDY_DIRECTOR",[28],{"name":29,"role":30,"phone":25,"phoneExt":31,"email":32},"Ping Li, phD","CONTACT",null,"lilyforever76@126.com",[34],{"facility":35,"status":36,"city":37,"state":31,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Shanghi Tongji Hospital (Tongji Hospital of Tongji University)","RECRUITING","Shanghai","620000","China","CN",{"type":42,"coordinates":43},"Point",[44,45],121.45806,31.22222,{"lat":45,"lon":44},[48],{"name":29,"role":30,"phone":25,"phoneExt":31,"email":31},{"type":50,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[52],{"name":53,"class":54},"Shanghai Tongji Hospital, Tongji University School of Medicine","OTHER","100612022","universal-car-t-cell-therapy-for-mm-100612022",false,"NCT07248176","Universal CAR-T Cell Therapy for MM","A Clinical Study on the Safety and Efficacy of Allogeneic CAR T Cells Targeting BCMA in the Treatment of Adult r\u002Fr Multiple Myeloma","Inclusion Criteria:\n\n1. Expected survival of at least 3 months;\n2. Subjects should have measurable disease that meets the IMWG 2016 criteria;\n3. Previously received at least two lines of prior anti-myeloma therapy ；\n4. Relapse , failure to achieve at least a minimal response, or disease progression after the last treatment ；\n5. BCMA positive；\n6. ECOG score 0-1；\n7. No severe impairment or suppression of liver, kidney, coagulation, bone marrow, or lung function.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women;\n2. History of other malignant tumors;\n3. Active autoimmune diseases requiring immunotherapy;\n4. Previously received allogeneic stem cell transplantation;\n5. Previous use of CAR-T cells or other genetically modified T cell therapies;\n6. Previously received targeted BCMA therapy;\n7. Severe cardiovascular disease;\n8. Active infection;\n9. Positive virology test;\n10. Clinically significant central nervous system (CNS) diseases or pathological changes.","ALL","18 Years",{"count":65,"type":66},6,"ESTIMATED","INTERVENTIONAL",[69],"NA","This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r\u002Fr multiple myeloma.",[72,73,74],"Multiple Myeloma","Multiple Myeloma in Relapse","Multiple Myeloma, Refractory","2025-11-28",{"date":77,"type":78},"2025-12-01","ACTUAL",{"date":80,"type":78},"2025-04-10",{"date":82,"type":66},"2028-04-18",{"name":5,"class":6},1]